Back to results
US 2020/0392156 A1Published application
Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors
AssigneePetra Pharma Corporation
InventorEdward A. KESICKI
Life of this patent
Estimating the term…
Abstract
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.
Claims28
A compound of Formula (I):
- or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof,
- wherein:
- A is aryl;
- B is heteroaryl, substituted with one or more R8, provided that when B is heteroaryl, B is not bonded through its heteroatom;
- X1 is C(R5);
- X2 is C(R5) or N;
- W is C(R6);
- R1 is —N(R2)C(O)R3, —C(O)N(R2)(R3), —P(O)(R2)(R3), or heteroaryl, wherein the heteroaryl is optionally substituted with one or more R7;
- R2 is independently, at each occurrence, C1-6 alkyl;
- R3 is independently, at each occurrence, C1-6 alkyl or C3-8 cycloalkyl;
- or
- R2 and R3 when taken together with the atom to which they are each attached form a heterocycle optionally substituted with one or more R4;
- R4 is independently —H or C1-6 alkyl;
- R5 is independently —H;
- R6 is —H, —N(R26)(R27), C1-6 alkoxy, heterocyclyl, C1-6 alkenyl, C1-6 haloalkyl, or C1-6 alkyl, wherein the alkyl, alkenyl, alkoxy, or heterocyclyl, is optionally substituted with one or more —OH, —CN, C1-6 alkyl, or heterocyclyl;
- R7 is C1-6 alkyl;
- R8 is heterocyclyl, —N(R9)(R10), or —OR10, wherein the heterocyclyl is optionally substituted with one or more R15;
- or
- two R8 groups, together with the atoms to which they are attached, form a heterocyclyl, optionally substituted with one or more R15;
- each R9 or R10 is independently, at each occurrence, C1-6 alkyl optionally substituted with one or more R11;
- R11 is —OH, heterocyclyl, —C(O)R17, or —C(O)N(R23)(R23), wherein the heterocyclyl is optionally substituted with one or more R17;
- R15 is —N(C1-6 alkyl)2, C1-6 alkyl, —C(O)N(R21)(R23), —(CH2)o—C(O)R23, or —C(O)OR23, wherein the alkyl, is optionally substituted with one or more R23;
- or
- two R15 groups, together with the atoms to which they are attached, form a heterocyclyl optionally substituted with one or more R20;
- R17 is halogen or C1-6 alkyl;
- R20 is independently oxo or C1-6 alkyl, wherein the C1-6 alkyl is substituted with heterocyclyl;
- R21 is —H or C1-6 alkyl;
- each R23 is independently C1-6 alkyl, optionally substituted with one or more —N(C1-6 alkyl)2;
- or
- two R23 together form a heterocyclyl, wherein the heterocyclyl is optionally substituted by C1-6 alkyl;
- R26 is —H or C1-6 alkyl;
- R27 is C1-6 alkyl, heterocyclyl, or cycloalkyl, wherein the alkyl, heterocyclyl, or cycloalkyl is optionally substituted with one or more halogen, —CN, —C(O)OH, —OH, or —NH2;
- and
- each o is independently 0-4,
- provided that R8 is not methoxy.
32 more elements
-29. (canceled)
Dependencies are inferred from the claim text.